Please login to the form below

Not currently logged in
Email:
Password:

Licensing deals

This page shows the latest Licensing deals news and features for those working in and with pharma, biotech and healthcare.

Gilead swoops on Forty Seven with $4.9bn all-cash deal

Gilead swoops on Forty Seven with $4.9bn all-cash deal

Takeover is latest in a string of billion-plus deals signed by Gilead. ... The takeover is the latest in a string of big billion dollar-plus licensing and acquisition deals signed by Gilead since the start of 2019 under new chief executive Daniel

Latest news

More from news
Approximately 2 fully matching, plus 86 partially matching documents found.

Latest Intelligence

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    the pipeline, the use of technology in medicine is expected to grow and so are the associated deals, mergers and acquisitions. ... They also can help identify collaboration opportunities including partnerships, licensing deals and merger or acquisition

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    returns. That includes an exit from areas like neurology – which predates Bourla’s appointment as CEO but was set up while he was COO – and a series of bolt-on deals ... Meanwhile, Galapagos looks set to continue adding to its pipeline through

  • A market-adapted agile approach to launch excellence A market-adapted agile approach to launch excellence

    Furthermore, increases. in region or market-specific licensing deals for launch products have led companies to devolve to region-specific cross-functional teams for tailored launch preparation, allowing different thinking to

  • The changing nature of approvals – what does the future hold? The changing nature of approvals – what does the future hold?

    Mega-mergers are also becoming less frequent; instead, we’re seeing fewer but larger deals. ... Based on CMR International data, since 2015 we have seen the number of drug commercialisation/licensing deals continue to gradually decline while the

  • Deal Watch October 2018

    Licensing &. research. collaboration. $550m. Novartis/. Mylan. TOBI Podhaler and TOBI solution for cystic fibrosis. ... Licensing &. collaboration. $40m. All deals are for worldwide rights unless stated otherwise:.

More from intelligence
Approximately 0 fully matching, plus 33 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics